Biotechnology 

iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery

The landscape of metagenomics and microbiome research is evolving at breakneck speed. As sequencing technologies improve and the demand for high-resolution, bias-free microbial data grows, the bottleneck is shifting from...

iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply-while early-onset...

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
ImmunoGenesis Announces the Formation of Scientific Advisory Board

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with...

ImmunoGenesis Announces the Formation of Scientific Advisory Board
SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel

SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A.

SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics

Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, announced today the launch of STAgora™, a next-generation platform for infectious disease analytics. Designed as a real-time infectious disease...

Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
SonoClear AS Receives FDA Breakthrough Designation for SonoClear® System

SonoClear AS today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has designated the SonoClear® System as a Breakthrough Device for use in intracranial...

SonoClear AS Receives FDA Breakthrough Designation for SonoClear® System
Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that...

Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
BioMarin Announces Completion of Acquisition of Inozyme

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately...

BioMarin Announces Completion of Acquisition of Inozyme
Nuravax, Institute for Molecular Medicine to Present Phase 1 Results and Phase 2 Design of Alzheimer's Vaccine AV-1959R at CTAD 2025

Nuravax Inc., a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced today that two oral presentations-the Phase 1 clinical results and the Phase 2 secondary...

Nuravax, Institute for Molecular Medicine to Present Phase 1 Results and Phase 2 Design of Alzheimer's Vaccine AV-1959R at CTAD 2025
Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve...

Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
Apnimed to Participate in Upcoming July Investor Conferences

Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing...

Apnimed to Participate in Upcoming July Investor Conferences
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced...

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering...

Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Frontage Announces Expansion of Business in Canada with New Leadership

As part of the strategy in expanding service offerings across the globe, Frontage Holdings Corporation is pleased to announce the appointment of Dr. Abdul Mutlib as the President of Frontage Laboratories, Canada. Dr....

Frontage Announces Expansion of Business in Canada with New Leadership
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing

On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical...

WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with...

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
Trip.com Group Pioneers a Greener, More Inclusive Global Travel Ecosystem in 2024 Sustainability Report

Trip.com Group, a leading global travel service provider, has released its latest Sustainability Report. The report highlights the company's significant progress in sustainability, centred around its "Friendly Four"...

Trip.com Group Pioneers a Greener, More Inclusive Global Travel Ecosystem in 2024 Sustainability Report
Atlas Corp. and subsidiary Seaspan Corporation release 2024 Sustainability Report

LONDON, UK, June 30, 2025 /PRNewswire/ - Atlas Corp. (Atlas) is proud to present its 2024 Sustainability Report, the fifth annual report on the company's Environment, Social, and Governance (ESG) initiatives. It covers...

Atlas Corp. and subsidiary Seaspan Corporation release 2024 Sustainability Report
Saluda Medical Appoints Barry Regan as Chief Executive Officer

Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the appointment...

Saluda Medical Appoints Barry Regan as Chief Executive Officer
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Nektar Therapeutics Announces Proposed Public Offering

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public...

Nektar Therapeutics Announces Proposed Public Offering
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten program for Becker and Duchenne muscular dystrophies.

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ: SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accordance with its...

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
Major Investment from Genome Canada to Help Advance ClarityDX Prostate Adoption Across Canada

Funding to Propel Widespread Adoption and Integration of Innovative Prostate Cancer Diagnostic Test into Canadian Healthcare

Major Investment from Genome Canada to Help Advance ClarityDX Prostate Adoption Across Canada
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and...

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix (NASDAQ: SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine...

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International...

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced...

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
Silvania Boosts Global Nature Platform through Expansion of Leadership, Strengthened Partnerships, and Brazil initiatives driving the Race to Belém

Silvania, a global natural capital investment platform launched with an initial USD $500 million commitment from Mercuria and its co-founders, aims to restore the planet's natural balance by mobilizing large-scale...

Silvania Boosts Global Nature Platform through Expansion of Leadership, Strengthened Partnerships, and Brazil initiatives driving the Race to Belém
AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is...

AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as...

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim...

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs

Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced the release of its 2024–2025 Sustainability Report. Noul has annually assessed its performance in economic,...

Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
SHEIN Hosts Third Campus Ambassador Retreat in Miami for More Than 150 U.S. Participants

SHEIN, the global fashion and lifestyle online retailer, hosted its third annual Campus Retreat in Miami from Thursday, June 26 to Saturday, June 28. The event kicked off with a Thursday evening welcome party at the SHEIN...

SHEIN Hosts Third Campus Ambassador Retreat in Miami for More Than 150 U.S. Participants
FDA Grants Breakthrough Device Designation to TOBY's AI-Powered Urine Test for Early Bladder Cancer Detection

TOBY, Inc., a biotech startup advancing non-invasive cancer detection through urine-based volatilomics and Artificial Intelligence, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

FDA Grants Breakthrough Device Designation to TOBY's AI-Powered Urine Test for Early Bladder Cancer Detection
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Actinogen Medical Limited (ASX: ACW) announces that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer's disease (AD) has now passed all screening tests and is scheduled...

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive...

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Simtra BioPharma Solutions Expands Halle/Westfalen, Germany Facility with the Addition of a New Production Building

Simtra BioPharma Solutions announced today that it completed the construction of its new production manufacturing building at its campus in Halle, Germany. As a leader in the CDMO industry specializing in sterile...

Simtra BioPharma Solutions Expands Halle/Westfalen, Germany Facility with the Addition of a New Production Building
Sinopec Wins Technological Innovation Award at the 2nd Sino-European Corporate ESG Best Practice Conference

China Petroleum & Chemical Corporation ("Sinopec", HKG: 0386) has won the "Best Scientific And Technological Innovation Practice" award at the 2nd Sino-European Corporate ESG Best Practice Conference (the...

Sinopec Wins Technological Innovation Award at the 2nd Sino-European Corporate ESG Best Practice Conference
ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging

ARTAN Bio, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and Syenex, an open-science genetic medicines platform company, today...

ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging
Shanghai Electric Ranks 47th on World Brand Lab's "China's 500 Most Valuable Brands" List with Brand Value of US$31.8 Billion

Shanghai Electric (SEHK: 2727, SSE: 601727) ranked among the top 50 in World Brand Lab's China's 500 Most Valuable Brands for the 10th consecutive year, with a record brand value of 228.565 billion yuan ($31.8...

Shanghai Electric Ranks 47th on World Brand Lab's "China's 500 Most Valuable Brands" List with Brand Value of US$31.8 Billion
Wesco Publishes 2025 Sustainability Report

Wesco International (NYSE:WCC), a leading provider of business-to-business distribution, logistics services and supply chain solutions, issued its annual sustainability report today. The report outlines Wesco's key...

Wesco Publishes 2025 Sustainability Report
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXiHigh™2.0, a high-throughput formulation development platform designed for...

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for...

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
Fosun International Garners Five Awards from Corporate Governance Asia

On 30 June 2025, Corporate Governance Asia presented the 15th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited ("Fosun International", "Fosun" or the...

Fosun International Garners Five Awards from Corporate Governance Asia
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular...

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology...

ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
Debut Named to TIME's List of the TIME100 Most Influential Companies 2025

Debut, the biotech beauty leader, was named to the TIME100 Most Influential Companies 2025. The annual list highlights 100 companies making an extraordinary impact around the world. Debut, named in the Innovators category...

Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of data at the 2025 Clinical Immunology Society (CIS) Annual Meeting by Dr. Ryan Dorfman, Chief Operating Officer of Prolytix. Dr....

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated...

Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key secondary...

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy

ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton...

ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular...

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies

As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed...

Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a partnership with Negedia, an initiative born from Fondazione Telethon to...

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July

Synthego, a leading provider of CRISPR solutions, today confirmed that its sale to Perceptive Advisors, a global life sciences investor known for backing leading biotech companies, is cleared to close. This transaction,...

Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site...

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its...

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Origin Agritech Announced Financial Results for the Six Months Ended March 31, 2025

Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced financial results for the six months ended March 31, 2025.

Origin Agritech Announced Financial Results for the Six Months Ended March 31, 2025
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center

Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its...

Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
Riverbend Nursery Holdings, LLC Announces Acquisition of James Greenhouses Inc.

Riverbend Nursery Holdings, LLC announces the acquisition of Colbert, Georgia based James Greenhouses, Inc, an industry leader in perennial liner production for wholesale growers in the United States. The transaction...

Riverbend Nursery Holdings, LLC Announces Acquisition of James Greenhouses Inc.
SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS
CIRCA Scientific Announces Successful Completion of Limited Market Release for CrossWise™ RF Transseptal Access System and Expands Compatibility to Additional Sheaths

CIRCA Scientific today announced the successful completion of the Limited Market Release (LMR) for its CrossWise™ RF Transseptal Access System, a key milestone following FDA clearance in September 2024. As part of the...

CIRCA Scientific Announces Successful Completion of Limited Market Release for CrossWise™ RF Transseptal Access System and Expands Compatibility to Additional Sheaths
Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was...

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

Angel Yeast (SH:600298) a global leader in yeast manufacturing, has announced that its Baiyang Biotechnology Park ("the Park") located in the Yichang High-Tech Zone will complete construction and commence trial production...

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September
JuliaHub Launches Dyad: Empowering Hardware Development at the Speed of Software

JuliaHub today unveiled Dyad, a powerful system that brings modern software agility to the world of hardware system design. A central theme behind our Dyad suite of tools is bringing together traditional physics-based...

JuliaHub Launches Dyad: Empowering Hardware Development at the Speed of Software
Spiber announces new partnerships with Manifattura Sesia and Achille Pinto

Spiber, a pioneer in man-made protein fibre (ISO 2076), produced using cutting-edge fermentation technology, is proud to announce its new partnerships with Manifattura Sesia S.r.l. and Achille Pinto S.p.A.

Spiber announces new partnerships with Manifattura Sesia and Achille Pinto
Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced that the first subject has been dosed in a Phase 1 clinical trial of CLY-124, a...

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease
Peptone Hosts In-Person Advisory Meeting With Leading Experts in Oncology, Drug Development and Medicinal Chemistry to Advance Small Molecule IDP-Targeted Treatment Solutions

Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases, successfully convened its H1 Advisory Board meeting this past week, uniting leading...

Peptone Hosts In-Person Advisory Meeting With Leading Experts in Oncology, Drug Development and Medicinal Chemistry to Advance Small Molecule IDP-Targeted Treatment Solutions
HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred...

HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
CMUH and Shine-On Biomedical Lead Taiwan's Push into Global Exosome-Based Precision Medicine

The NextGen EV Therapeutics Forum, hosted by China Medical University and Healthcare System, bringing together leading scientists, clinical experts, and biotech industry leaders from Taiwan and the United States to explore...

CMUH and Shine-On Biomedical Lead Taiwan's Push into Global Exosome-Based Precision Medicine
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating...

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management

PITTSBURGH, June 26, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at...

Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management
Avivomed Names Dan Brounstein as Next Chief Executive Officer

Avivomed, Inc., a privately held, clinical-stage, medical device company, announced the appointment of Dan Brounstein as its new Chief Executive Officer and Board Member. Brounstein succeeds CEO Steve Masson, who retired...

Avivomed Names Dan Brounstein as Next Chief Executive Officer
Kraton Corporation Releases 2024 Sustainability Report

Kraton Corporation, a leading global producer of specialty polymers and high-value biobased products derived from pine wood pulping co-products, proudly announces the release of its 2024 Sustainability Report, titled...

Kraton Corporation Releases 2024 Sustainability Report
BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to its highly...

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New...

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
Countries Urged to Establish National Refrigeration Committees to Tackle Food, Health, Animals and Climate Challenges

On the occasion of World Refrigeration Day, the International Institute of Refrigeration (IIR) is calling on all countries to recognise refrigeration as a critical infrastructure for health, food security, energy...

Countries Urged to Establish National Refrigeration Committees to Tackle Food, Health, Animals and Climate Challenges
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that...

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR...

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Speranza Therapeutics and Sunshine Labs Announce Strategic Global Partnership to Expand Access to Life-Saving Harm Reduction Solutions

Speranza Therapeutics is proud to announce a strategic partnership with Sunshine Labs, a global leader in harm reduction, safer supply, and science-backed therapeutic innovation. This groundbreaking collaboration is a...

Speranza Therapeutics and Sunshine Labs Announce Strategic Global Partnership to Expand Access to Life-Saving Harm Reduction Solutions
Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing

Medeologix, a leading brand in medical device manufacturing, today announced a significant advancement in their production capabilities that slashes lead times for premium PET heat shrink tubing to just 3 weeks.

Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing
Vetigenics Launches CHECKMATE?K9-First Dual Immune Checkpoint Inhibitor Study in Dogs with Solid Tumors

In a research initiative inspired by landmark dual immune checkpoint inhibitor (ICI) studies in human cancer, Vetigenics today announced dosing of the first patient in its CHECKMATE K9 pilot clinical study at the...

Vetigenics Launches CHECKMATE?K9-First Dual Immune Checkpoint Inhibitor Study in Dogs with Solid Tumors
Alafair Biosciences Announces First Patient Enrolled in Multi-Center Study Evaluating VersaWrap® Tendon Protector for Achilles Repair

Alafair Biosciences, Inc., a leading innovator in medical device technology, is pleased to announce the first patient enrolled at UC Davis Foot and Ankle Orthopaedics Clinic, as part of a prospective, multi-center,...

Alafair Biosciences Announces First Patient Enrolled in Multi-Center Study Evaluating VersaWrap® Tendon Protector for Achilles Repair
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty live

Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic...

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty live
Avance Biosciences Launches NGS Center of Excellence in Houston

Avance Biosciences is proud to announce the launch of its Next-Generation Sequencing (NGS) Center of Excellence, a purpose-built facility designed to unify and enhance the company's sequencing capabilities across all...

Avance Biosciences Launches NGS Center of Excellence in Houston
Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor a for the Treatment of Platinum-Resistant Ovarian Cancer

GUANGZHOU, China, June 25, 2025 /PRNewswire/ - Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing...

Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor a for the Treatment of Platinum-Resistant Ovarian Cancer
EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas

EDAN Instruments, Inc. (300206.SZ), a healthcare company and medical device manufacturer, officially celebrated the opening of its new subsidiary, EDAN MEDICAL MÉXICO S de R.L. de C.V., with a ribbon-cutting ceremony held...

EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS).An Objective Response...

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and SteinCares, a leading specialty healthcare company in Latin America, today...

Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Blue Earth Therapeutics today announced radiation dosimetry results for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy at the Society for Nuclear Medicine and Molecular Imaging...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
£7.5 million Longitude Prize on ALS launches

The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral...

£7.5 million Longitude Prize on ALS launches
Zymo Research Unveils MultiOmiX Workstation with Show-Stopping Launch at ASM Microbe 2025

Zymo Research stole the spotlight at the American Society for Microbiology (ASM) Microbe 2025 conference with the official debut of the MultiOmiX Workstation, a next-generation platform delivering fully automated,...

Zymo Research Unveils MultiOmiX Workstation with Show-Stopping Launch at ASM Microbe 2025